Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This pilot study detailed the use of Hair-to-Hair-matching technology™ in a clinical trial to assess botulinum toxin's efficacy in treating male androgenetic alopecia, providing a precise method for evaluating hair count and thickness changes over time.

In this study, patients with resistant alopecia areata treated with 35% trichloroacetic acid showed significantly better outcomes compared to those receiving superficial cryotherapy, with TCA demonstrating "excellent" results in 37.5% of cases versus 6.25% for cryotherapy.

In this case report, a woman with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvements in both conditions after six months of treatment with tofacitinib, a Janus Kinase inhibitor, with no recurrence or adverse events noted during a two-year follow-up.

In this pilot study, baicalin-containing serum significantly decreased hair loss and increased hair growth after two months in participants with telogen effluvium, as subjective and objective assessments showed statistically significant improvements in hair thickness and density.

This study found that tannic acid accelerated wound healing in rats by modulating inflammatory cytokines, increasing growth factors, and activating the Erk 1/2 pathway.

In an outpatient cardiology center, this study found that introducing the AHA/ACC ABI screening protocol significantly increased the frequency of ABI ordering by 31.6% for symptomatic patients.

Using truncal anesthesia on the supraorbital nerve reduces pain in hair loss treatments and improves patient comfort.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

Tretinoin gel is safe for sun exposure, but tacalcitol doesn't significantly improve non-segmental vitiligo.

This case report highlights a rare association between congenital triangular alopecia and vitiligo, noting that treatment with tofacitinib improved the patient's vitiligo but not the alopecia.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

This study found that twice-daily oral baricitinib at a 2-mg dose showed promising results in treating refractory alopecia areata, particularly among Chinese patients, with 64% achieving significant hair regrowth, although none attained complete hair regrowth. Adverse events were mild and included nausea and folliculitis.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

In this animal study, atorvastatin co-administered with trastuzumab reversed trastuzumab-induced cognitive impairment (chemo-brain) and improved its anti-cancer efficacy without causing hair loss.

In this review, BTXA treatment was reported to effectively increase hair density and improve follicle health in androgenetic alopecia patients by enhancing scalp blood flow and reducing inflammation, without significant adverse effects.

In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.

This case study reports significant improvements in joint pain and hair regrowth in a 31-year-old female with alopecia universalis, psoriasis vulgaris, and psoriatic arthritis using a combination of tofacitinib and methotrexate after other treatments failed.

The authors concluded that intralesional triamcinolone acetonide may benefit patients with patch-type alopecia areata, but the evidence is limited due to small, bias-prone studies with variations in treatment protocols.

This study found that combining cyproterone acetate with testosterone enanthate was highly effective in suppressing spermatogenesis, suggesting potential as a reversible male contraceptive method.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

This study reports a case of a 59-year-old female with refractory follicular mucinosis and diffuse scalp alopecia who achieved complete clinical remission following treatment with a combination of topical tacalcitol and photodynamic therapy.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

This study assessed oral tofacitinib's effectiveness and safety in treating different forms of alopecia, finding that 80% of patients experienced hair regrowth improvements over 24 weeks with no adverse events reported.

This study found that intralesional triamcinolone was more effective than topical betamethasone for hair regrowth in patients with localized alopecia areata.

This study observed that oral administration of BeauTop, a Chinese herbal medicine, significantly increased hair growth indicators, including VEGF expression, hair follicles, and hair coverage in C57BL/6 mice.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

This study found that baricitinib significantly reduced hair loss in patients with severe alopecia areata, decreasing the mean SALT score from 96.6 to 48 over 24 weeks, with no patients dropping out and only mild adverse events in 12.7% of participants.

Tanshinone IIA helps protect tissue from low oxygen damage by activating certain cell pathways.

In this study, researchers found that patients with severe alopecia areata who respond to baricitinib treatment within six months may improve clinically within a year, while those with very severe disease may require at least a year for evidence of treatment effect.

This study observed that tofacitinib therapy over about 16 weeks had a positive effect in children with alopecia areata, reducing the SALT index significantly in some patients.